HRAS mutations have been mainly documented in HNSCC, salivary glands, pheochromocytoma and bladder cancers [10,13,14,20,21,23,24,25,26,27,28,29] (Figure 2). This evidence concerns the gene HRAS and urinary bladder cancer.